Embecta is global medical device company focused on providing solutions to improve the health and wellbeing of people living with diabetes. Co. has a portfolio of marketed products, including various of pen needles, syringes and safety devices, which are complemented by its proprietary digital applications. Co.'s pen needles are sterile, single-use, medical devices, designed to be used in conjunction with insulin pens and are used to inject insulin or other diabetes medications. Co. also sells safety pen needles, which include resin injection-molded shields on both ends of the cannula that automatically deploy to help prevent needlestick exposure and injury during injection and disposal. The EMBC average annual return since 2022 is shown above.
The Average Annual Return on the EMBC average annual return since 2022 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether EMBC average annual return since 2022 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the EMBC average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|